Equine Infectious Anemia Virus Vaccine

Creative Biolabs is a world leader in the field of vaccine development and can offer high-quality viral vaccines for use in prevention of viral infections. By consistently delivering the highest standards of quality, professionalism, and integrity, we want to become the partner of a choice for your requirements. Equine infectious anemia is a reportable disease in the United States, and federal law prohibits interstate travel of infected animals except under special circumstances. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services against equine infectious anemia virus.

Equine Infectious Anemia Virus Vaccine - Creative Biolabs

Equine infectious anemia (EIA) is a chronic, noncontagious, relapsing infectious disease of horses and other equidae caused by a non-oncogenic retrovirus called equine infectious anemia virus (EIAV). Recrudescence of acute EIA is the result of antigenic variation of the surface glycoprotein of EIA virus. EIAV is an RNA virus classified in the Lentivirus genus, family Retroviridae. The EIAV genome formed by gag (group-specific antigen), pol (polymerase), and env (envelope) genes, and flanked at both ends by long terminal repeats. The clinical signs of EIA present as an acute, subacute, or chronic infection and on occasion, the virus can be a cause of significant morbidity and mortality. EIAV is a macrophage-tropic equine lentivirus that has been used extensively as a model for HIV-1 persistence and pathogenesis and for AIDS vaccine development.

Live Attenuated EIAV Vaccine

The live EIAV vaccine was developed by in vitro attenuation and it has been demonstrated to induce protective immunity under laboratory and natural EIAV infection conditions. This attenuated lentiviral vaccine was developed by successive passaging of a field-isolated virulent strain in different hosts and cultivated cells. The vaccine applied on a large scale that has been shown to be a vaccine may achieve an apparent 100% protection from homologous virus challenge. Moreover, it is effective in controlling the prevalence of EIA in China and does not cause obvious histopathological lesions or clinical symptoms and that it induces a unique cytokine response profile. Therefore, these features are considered essential for it to function as an effective live vaccine.

Subunit Vaccines

The subunit proteins of EIAV may play an important role in the vaccine development. The mutations of these subunit gene generated by site-directed mutagenesis resulted in cloned viruses with enhanced resistance to serum neutralizing antibodies that were also able to recognize parental viruses. A subunit vaccine enriched in EIAV envelope glycoproteins and prevented infection from homologous challenge. This vaccine can stimulate EIAV-specific cell-mediated immunity. In general, immature immune responses were associated with lack of protection or enhancement by the experimental vaccine, while mature immune responses were necessary for protective vaccine immunity. The level of protection observed with the vaccine correlates with the level of divergence of the viral env, indicating the importance of exposure to variant env species to achieve the most effective vaccine immunity. Thus, env gene of EIAV has the specific antibody avidity and can be the most useful candidate for the vaccine development to protect against EIAV.

Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of viral vaccine development. We have experts who are able to help you with the vaccine development against equine infectious anemia virus. Our scientists are confident in offering the best services and products upon request!


All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.


Online Inquiry

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONTACT US

USA

Tel:
Fax:
Email:
UK

Tel:
Email:
Germany

Tel:
Email:


Follow us on